Larsson, Peter
Pettersson, Daniella
Olsson, Maxim
Sarathchandra, Sithumini
Abramsson, Alexandra
Zetterberg, Henrik
Ittner, Ella
Forssell-Aronsson, Eva
Kovács, Anikó
Karlsson, Per http://orcid.org/0000-0003-4841-2672
Helou, Khalil
Parris, Toshima Z. http://orcid.org/0000-0003-0834-5540
Funding for this research was provided by:
Stiftelserna Wilhelm och Martina Lundgrens (2020-3473)
Anna-Lisa och Bror Björnssons Stiftelse
Stiftelsen Assar Gabrielssons Fond (FB19-04, FB20-61, FB21-46, FB22-68)
Vetenskapsrådet (#2023-00356; #2022-01018 and #2019-02397)
Article History
Received: 4 June 2023
Revised: 10 January 2024
Accepted: 15 January 2024
First Online: 29 January 2024
Competing interests
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare no competing interests.
: Not applicable.
: Not applicable.